REFERENCES

Publication Details

1.
Sen CK, Gordillo GM, Roy S, et al. Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen. 2009;17(6):763–71. [PMC free article: PMC2810192] [PubMed: 19903300]
2.
Jones KR, Fennie K, Lenihan A. Evidence-based management of chronic wounds. Adv Skin Wound Care. 2007;20(11):591–600. [PubMed: 17975367]
3.
Spentzouris G, Labropoulos N. The evaluation of lower-extremity ulcers. Semin Intervent Radiol. 2009;26(4):286–95. [PMC free article: PMC3036466] [PubMed: 21326538]
4.
Ayello EA. What does the wound say? Why determining etiology is essential for appropriate wound care. Adv Skin Wound Care. 2005;18(2):98–109. [PubMed: 15788915]
5.
American Society of Plastic Surgeons. Evidence-based Clinical Practice Guideline: Chronic Wounds of the Lower Extremity. 2007. [September 2012]. Available at: http://www​.plasticsurgery​.org/Documents/medical-professionals​/health-policy/evidence-practice​/Evidence-based-Clinical-Practice-Guideline-Chronic-Wounds-of-the-Lower-Extremity.pdf.
6.
Hess CT. Lower-extremity wound checklist. Adv Skin Wound Care. 2011;24(3):144. [PubMed: 21326026]
7.
McCulloch DK, de Asia RJ. Management of diabetic foot lesions. In: Basow DS, editor. UpToDate. Waltham, MA: 2012.
8.
Wagner FW Jr. The dysvascular foot: a system for diagnosis and treatment. Foot Ankle. 1981;2(2):64–122. [PubMed: 7319435]
9.
Lavery LA, Armstrong DG, Harkless LB. Classification of diabetic foot wounds. J Foot Surg. 1996;35(6):528–31. [PubMed: 8986890]
10.
Valencia IC, Falabella H, Kirsner RS, Eaglstein WH. Chronic venous insufficiency and venous leg ulceration. J Am Acad Dermatol. 2001;44:401–21. [PubMed: 11209109]
11.
Nelzen O, Bergqvist D, Lindhagen A. Venous and non-venous leg ulcers: clinical history and appearance in a population study. Br J Surg. 1994;81(2):182–7. [PubMed: 8156328]
12.
Mayberry JC, Moneta GL, Taylor LM Jr, Porter JM. Fifteen-year results of ambulatory compression therapy for chronic venous ulcers. Surgery. 1991;109:575–81. [PubMed: 2020902]
13.
Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration; 2011. [updated March 2011] Available from www​.cochrane-handbook.org.
14.
Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--agency for healthcare research and quality and the effective health-care program. J Clin Epidemiol. 2010 May;63(5):513–23. [PubMed: 19595577]
15.
Blume P, Driver VR, Tallis AJ, et al. Formulated collagen gel accelerates healing rate immediately after application in patients with diabetic neuropathic foot ulcers. Wound Repair Regen. 2011;19(3):302–8. [PMC free article: PMC3443373] [PubMed: 21371164]
16.
Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg. 2002;137(7):822–7. [PubMed: 12093340]
17.
Donaghue VM, Chrzan JS, Rosenblum BI, Giurini JM, Habershaw GM, Veves A. Evaluation of a collagen-alginate wound dressing in the management of diabetic foot ulcers. Adv Wound Care. 1998;11(3):114–9. [PubMed: 9729942]
18.
Reyzelman A, Crews RT, Moore JC, et al. Clinical effectiveness of an acellular dermal regenerative tissue matrix compared to standard wound management in healing diabetic foot ulcers: a prospective, randomised, multicentre study. Int Wound J. 2009;6(3):196–208. [PMC free article: PMC7951349] [PubMed: 19368581]
19.
Niezgoda JA, Van Gils CC, Frykberg RG, Hodde JP. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers. Adv Skin Wound Care. 2005;18(5 Pt 1):258–66. [PubMed: 15942317]
20.
Landsman A, Roukis TS, DeFronzo DJ, Agnew P, Petranto RD, Surprenant M. Living cells or collagen matrix: which is more beneficial in the treatment of diabetic foot ulcers? Wounds. 2008;20(5):111–6. [PubMed: 25942411]
21.
Gentzkow GD, Iwasaki SD, Hershon KS, et al. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care. 1996;19(4):350–4. [PubMed: 8729158]
22.
Naughton G, Mansbridge J, Gentzkow G. A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. Artif Organs. 1997;21(11):1203–10. [PubMed: 9384327]
23.
Marston WA, Hanft J, Norwood P, Pollak R., Dermagraft Diabetic Foot Ulcer Study G. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care. 2003;26(6):1701–5. [PubMed: 12766097]
24.
Veves A, Falanga V, Armstrong DG, Sabolinski ML., Apligraf Diabetic Foot Ulcer S. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. 2001;24(2):290–5. [PubMed: 11213881]
25.
Edmonds M., European, Australian Apligraf Diabetic Foot Ulcer Study G. Apligraf in the treatment of neuropathic diabetic foot ulcers. Int J Low Extrem Wounds. 2009;8(1):11–8. [PubMed: 19189997]
26.
DiDomenico L, Emch KJ, Landsman AR, Landsman A. A prospective comparison of diabetic foot ulcers treated with either a cryopreserved skin allograft or a bioengineered skin substitute. Wounds. 2011;23(7):184–9. [PubMed: 25879172]
27.
Aminian B, Shams M, Soveyd M, Omrani GR. Topical autologous platelet-derived growth factors in the treatment of chronic diabetic ulcers. Arch Iranian Med. 2000;3(2):55–9.
28.
Agrawal RP, Jhajharia A, Mohta N, Dogra R, Chaudhari V, Nayak KC. Use of a platelet-derived growth factor gel in chronic diabetic foot ulcers. Diabetic Foot J. 2009;12(2):80–8.
29.
Hardikar JV, Reddy YC, Bung DD, et al. Efficacy of recombinant human platelet-derived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, double-blind, placebo-controlled study in India. Wounds. 2005;17(6):141–52.
30.
Bhansali A, Venkatesh S, Dutta P, Dhillon MS, Das S, Agrawal A. Which is the better option: recombinant human PDGF-BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off-loaded by a customized contact cast? Diabetes Res Clin Pract. 2009;83(1):e13–16. [PubMed: 19081156]
31.
Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care. 1998;21(5):822–7. [PubMed: 9589248]
32.
Jaiswal SS, Gambhir RPS, Agrawal A, Harish S. Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers. Indian J Surg. 2010;72(1):31–5. [PMC free article: PMC3452554] [PubMed: 23133200]
33.
Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J Vasc Surg. 1995;21(1):71–78. [PubMed: 7823364]
34.
Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers. Plast Reconstr Surg. 2006;117 Suppl 7:143–9S. [PubMed: 16799381]
35.
d'Hemecourt PA, Smiell JM, Karim MR. Sodium carboxymethycellulose aqueous-based gel vs becaplermin gel in patients with nonhealing lower extremity diabetic ulcers. Wounds. 1998;10(3):69–75.
36.
Saad Setta H, Elshahat A, Elsherbiny K, Massoud K, Safe I. Platelet-rich plasma versus platelet-poor plasma in the management of chronic diabetic foot ulcers: a comparative study. Int Wound J. 2011;8(3):307–12. [PMC free article: PMC7950579] [PubMed: 21470370]
37.
Driver VR, Hanft J, Fylling CP, Beriou JM., Autologel Diabetic Foot Ulcer Study G. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage. 2006;52(6):68–70. 74 passim. [PubMed: 16799184]
38.
Belcaro G, Cesarone MR, Errichi BM, et al. Venous and diabetic ulcerations: management with topical multivalent silver oxide ointment. Panminerva Med. 2010;52(2 Suppl 1):37–42. [PubMed: 20657533]
39.
Jacobs AM, Tomczak R. Evaluation of Bensal HP for the treatment of diabetic foot ulcers. Adv Skin Wound Care. 2008;21(10):461–5. [PubMed: 18836324]
40.
Jude EB, Apelqvist J, Spraul M, Martini J., Silver Dressing Study G. Prospective randomized controlled study of Hydrofiber dressing containing ionic silver or calcium alginate dressings in non-ischaemic diabetic foot ulcers. Diabet Med. 2007;24(3):280–8. [PubMed: 17305788]
41.
Viswanathan V, Kesavan R, Kavitha KV, Kumpatla S. A pilot study on the effects of a polyherbal formulation cream on diabetic foot ulcers. Indian J Med Res. 2011;134(2):168–73. [PMC free article: PMC3181016] [PubMed: 21911968]
42.
Blume PA, Walters J, Payne W, Ayala J, Lantis J. Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. Diabetes Care. 2008;31(4):631–6. [PubMed: 18162494]
43.
Karatepe O, Eken I, Acet E, et al. Vacuum assisted closure improves the quality of life in patients with diabetic foot. Acta Chir Belg. 2011;111(5):298–302. [PubMed: 22191131]
44.
McCallon SK, Knight CA, Valiulus JP, Cunningham MW, McCulloch JM, Farinas LP. Vacuum-assisted closure versus saline-moistened gauze in the healing of postoperative diabetic foot wounds. Ostomy Wound Manage. 2000;46(8):28–32. 34. [PubMed: 11189545]
45.
Wang CJ, Wu RW, Yang YJ. Treatment of diabetic foot ulcers: a comparative study of extracorporeal shockwave therapy and hyperbaric oxygen therapy. Diabetes Res Clin Pract. 2011;92(2):187–93. [PubMed: 21310502]
46.
Londahl M, Katzman P, Nilsson A, Hammarlund C. Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. Diabetes Care. 2010;33(5):998–1003. [PMC free article: PMC2858204] [PubMed: 20427683]
47.
Duzgun AP, Satir HZ, Ozozan O, Saylam B, Kulah B, Coskun F. Effect of hyperbaric oxygen therapy on healing of diabetic foot ulcers. J Foot Ankle Surg. 2008;47(6):515–9. [PubMed: 19239860]
48.
Kessler L, Bilbault P, Ortega F, et al. Hyperbaric oxygenation accelerates the healing rate of nonischemic chronic diabetic foot ulcers: a prospective randomized study. Diabetes Care. 2003;26(8):2378–82. [PubMed: 12882865]
49.
Abidia A, Laden G, Kuhan G, et al. The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial. Eur J Vasc Endovasc Surg. 2003;25(6):513–8. [PubMed: 12787692]
50.
Wainstein J, Feldbrin Z, Boaz M, Harman-Boehm I. Efficacy of ozone-oxygen therapy for the treatment of diabetic foot ulcers. Diabetes Technol Ther. 2011;13(12):1255–60. [PubMed: 21751891]
51.
Motzkau M, Tautenhahn J, Lehnert H, Lobmann R. Expression of matrix-metalloproteases in the fluid of chronic diabetic foot wounds treated with a protease absorbent dressing. Exp Clin Endocrinol. 2011;119(5):286–90. [PubMed: 21031342]
52.
Vin F, Teot L, Meaume S. The healing properties of Promogran in venous leg ulcers. J Wound Care. 2002;11(9):335–41. [PubMed: 12430368]
53.
Mostow EN, Haraway GD, Dalsing M, Hodde JP, King D., Group OVUS. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. J Vasc Surg. 2005;41(5):837–43. [PubMed: 15886669]
54.
Falanga V, Margolis D, Alvarez O, et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Human Skin Equivalent Investigators Group. Arch Dermatol. 1998;134(3):293–300. [PubMed: 9521027]
55.
Falanga V, Sabolinski M. A bilayered living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen. 1999;7(4):201–7. [PubMed: 10781211]
56.
Krishnamoorthy L, Harding K, Griffiths D. The clinical and histological effects of Dermagraft in the healing of chronic venous leg ulcers. Phlebology. 2003;18(1):12–22.
57.
Omar AA, Mavor AID, Jones AM, Homer-Vanniasinkam S. Treatment of venous leg ulcers with Dermagraft. Eur J Vasc Endovasc Surg. 2004;27(6):666–72. [PubMed: 15121121]
58.
Lindgren C, Marcusson JA, Toftgard R. Treatment of venous leg ulcers with cryopreserved cultured allogeneic keratinocytes: a prospective open controlled study. Br J Dermatol. 1998;139(2):271–5. [PubMed: 9767241]
59.
Navratilova Z, Slonkova V, Semradova V, Adler J. Cryopreserved and lyophilized cultured epidermal allografts in the treatment of leg ulcers: a pilot study. J Eur Acad Dermatol Venereol. 2004;18(2):173–9. [PubMed: 15009297]
60.
Harding KG, Krieg T, Eming SA, et al. Efficacy and safety of the freeze-dried cultured human keratinocyte lysate, LyphoDerm 0.9%, in the treatment of hard-to-heal venous leg ulcers. Wound Repair Regen. 2005;13(2):138–47. [PubMed: 15828938]
61.
Vanscheidt W, Ukat A, Horak V, et al. Treatment of recalcitrant venous leg ulcers with autologous keratinocytes in fibrin sealant: a multinational randomized controlled clinical trial. Wound Repair Regen. 2007;15(3):308–15. [PubMed: 17537117]
62.
Stacey MC, Mata SD, Trengove NJ, Mather CA. Randomised double-blind placebo controlled trial of topical autologous platelet lysate in venous ulcer healing. Eur J Vasc Endovasc Surg. 2000;20(3):296–301. [PubMed: 10986030]
63.
Bishop JB, Phillips LG, Mustoe TA, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992;16(2):251–7. [PubMed: 1495150]
64.
Blair SD, Backhouse CM, Wright DDI, Riddle E, McCollum CN. Do dressings influence the healing of chronic venous ulcers? Phlebology. 1988;3:129–34.
65.
Dimakakos E, Katsenis K, Kalemikerakis J, et al. Infected Venous Leg Ulcers: Management With Silver-releasing Foam Dressing. Wounds. 2009;21(1):4–8. [PubMed: 25904580]
66.
Harding K, Gottrup F, Jawien A, et al. A prospective, multi-centre, randomised, open label, parallel, comparative study to evaluate effects of AQUACEL Ag and Urgotul Silver dressing on healing of chronic venous leg ulcers. Int Wound J. 2011;9(3):285–94. [PMC free article: PMC7950382] [PubMed: 22066961]
67.
Michaels JA, Campbell WB, King BM, Palfreyman SJ, Shackley P, Stevenson M. Randomized controlled trial and cost-effectiveness analysis of silver-donating antimicrobial dressings for venous leg ulcers (VULCAN trial). Br J Surg. 2009;96:1147–56. [PubMed: 19787753]
68.
Michaels JA, Campbell WB, King BM, et al. A prospective randomised controlled trial and economic modelling of antimicrobial silver dressings versus non-adherent control dressings for venous leg ulcers: the VULCAN trial. Health Technol Assess. 2009;13(56):1–114. [PubMed: 19939335]
69.
Schuler JJ, Maibenco T, Megerman J, Ware M, Montalvo J. Treatment of chronic venous ulcers using sequential gradient intermittent pneumatic compression. Phlebology. 1996;11:111–6.
70.
Ieran M, Zaffuto S, Bagnacani M, Annovi M, Moratti A, Cadossi R. Effect of low frequency pulsing electromagnetic fields on skin ulcers of venous origin in humans: a double-blind study. J Orthop Res. 1990;8(2):276–82. [PubMed: 2303961]
71.
Kenkre JE, Hobbs FD, Carter YH, Holder RL, Holmes EP. A randomized controlled trial of electromagnetic therapy in the primary care management of venous leg ulceration. Fam Pract. 1996;13(3):236–41. [PubMed: 8671131]
72.
Hammarlund C, Sundberg T. Hyperbaric oxygen reduced size of chronic leg ulcers: a randomized double-blind study. Plast Reconstr Surg. 1994;93(4):829–33. [PubMed: 8134442]
73.
Chang DW, Sanchez LA, Veith FJ, Wain RA, Okhi T, Suggs WD. Can a tissue-engineered skin graft improve healing of lower extremity foot wounds after revascularization? Ann Vasc Surg. 2000;14(1):44–9. [PubMed: 10629263]
74.
Brigido SA. The use of an acellular dermal regenerative tissue matrix in the treatment of lower extremity wounds: a prospective 16-week pilot study. Int Wound J. 2006;3(3):181–7. [PMC free article: PMC7951702] [PubMed: 16984575]
75.
Romanelli M, Dini V, Bertone M, Barbanera S, Brilli C. OASIS wound matrix versus Hyaloskin in the treatment of difficult-to-heal wounds of mixed arterial/venous aetiology. Int Wound J. 2007;4(1):3–7. [PMC free article: PMC7951303] [PubMed: 17425543]
76.
Romanelli M, Dini V, Bertone MS. Randomized comparison of OASIS wound matrix versus moist wound dressing in the treatment of difficult-to-heal wounds of mixed arterial/venous etiology. Adv Skin Wound Care. 2010;23(1):34–8. [PubMed: 20101114]
77.
Jorgensen B, Price P, Andersen KE, et al. The silver-releasing foam dressing, Contreet Foam, promotes faster healing of critically colonised venous leg ulcers: a randomised, controlled trial. Int Wound J. 2005;2(1):64–73. [PMC free article: PMC7951198] [PubMed: 16722854]
78.
Miller CN, Newall N, Kapp SE, et al. A randomized-controlled trial comparing cadexomer iodine and nanocrystalline silver on the healing of leg ulcers. Wound Rep Reg. 2010;18(4):359–67. [PubMed: 20636550]
79.
Fumal I, Braham C, Paquet P, Pierard-Franchimont C, Pierard GE. The beneficial toxicity paradox of antimicrobials in leg ulcer healing impaired by a polymicrobial flora: a proof-of-concept study. Dermatology. 2002;204 Suppl 1:70–4. [PubMed: 12011525]
80.
Vuerstaek JD, Vainas T, Wuite J, Nelemans P, Neumann MH, Veraart JC. State-of-the-art treatment of chronic leg ulcers: A randomized controlled trial comparing vacuum-assisted closure (V.A.C.) with modern wound dressings. J Vasc Surg. 2006;44(5):1029–37. [PubMed: 17000077]
81.
Armstrong DG, Lavery LA., Diabetic Foot Study C. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet. 2005;366(9498):1704–10. [PubMed: 16291063]
82.
Apelqvist J, Armstrong DG, Lavery LA, Boulton AJM. Resource utilization and economic costs of care based on a randomized trial of vacuum-assisted closure therapy in the treatment of diabetic foot wounds. Am J Surg. 2008;195:782–8. [PubMed: 18355797]
83.
Fife CE. Wound Care in the 21st Century. US Surgery. 2007:63–64.
84.
Wu SC, Marston W, Armstrong DG. Wound care: the role of advanced wound-healing technologies. J Am Podiatr Med Assoc. 2010;100(5):385–94. [PubMed: 20847352]
85.
Sullivan N, Snyder DL, Tipton K, Uhl S, Schoelles KM. Technology Assessment Report. 2009. Negative pressure wound therapy devices. Prepared under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2007-10063) [PubMed: 25392896]
86.
Ubbink DT, Westerbos SJ, Evans D, Land L, Vermeulen H. Topical negative pressure for treating chronic wounds. Cochrane Database of Systematic Reviews. 2008;(3) Art. No.: CD001989. [PubMed: 18646080]
87.
Noble-Bell G, Forbes A. A systematic review of the effectiveness of negative pressure wound therapy in the management of diabetes foot ulcers. Int Wound J. 2008;5:233–42. [PMC free article: PMC7951535] [PubMed: 18494629]
88.
Armstrong DG, Nguyen HC, Lavery LA, van Schie CH, Boulton AJ, Harkless LB. Off-loading the diabetic foot wound: a randomized clinical trial. Diabetes Care. 2001;24(6):1019–22. [PubMed: 11375363]
89.
Katz IA, Harlan A, Miranda-Palma B, et al. A randomized trial of two irremovable off-loading devices in the management of plantar neuropathic diabetic foot ulcers. Diabetes Care. 2005;28(3):591–600. [PubMed: 15735187]
90.
Mustoe TA, O'Shaughnessy K, Kloeters O. Chronic wound pathogenesis and current treatment strategies: a unifying hypothesis. Plast Reconstr Surg. 2006;117 Suppl 7:35S–41S. [PubMed: 16799373]
91.
O'Meara S, Cullum NA, Nelson EA. Compression for venous leg ulcers. Cochrane Database of Systematic Reviews. 2009;(1):CD000265. [PubMed: 19160178]
92.
Gottrup F, Apelqvist J, Price P. Outcomes in controlled and comparative studies on non-healing wounds: recommendations to improve the quality of evidence in wound management. J Wound Care. 2010;19:239–68. [PubMed: 20551864]